The novel CRAFITY score—which takes into account C-reactive protein (CRP), alpha-foetoprotein (AFP), and immunotherapy—can be used to reliably assess survival and radiological response in hepatocellular carcinoma (HCC), a recent study has found. Future validation is needed before CRAFITY can be deployed to the clinics.
Exposure to environmental contaminants, particularly perfluorinated alkyl substances, seems to disrupt bile acid and lipid metabolism, both key hepatic metabolic pathways that are known to be dysregulated in nonalcoholic fatty liver disease (NAFLD), a recent study has found. Such an effect seems to be more pronounced in women.
The consumption of fructose from fruit juice and sugar sweetened beverages (SSBs), but not from fruit, is associated with higher intrahepatic lipid (IHL) content, according to data from a cross-sectional study presented at EASD 2021.
Recent research has found that mutations in the human EZH2 and CCND1 genes may be potential novel biomarkers for liver cancer. The tumour mutation burden (TMB) also appears to be an important prognostic factor and affects patient survival.
Most cases of paediatric acute liver failure (PALF) in Singapore are still of indeterminate aetiology, according to a recent single-centre study. Given the poor survival prospects of PALF, timely liver transplantation (LT) is critical.
Post hoc analyses evaluating adherence based on pill count in patients prescribed 8- or 12-week glecaprevir/pibrentasvir (G/P) reveal that treatment duration influences adherence rates and further stress the concept of “treatment forgiveness” with direct-acting antiviral therapies.
Endoscopic retrograde cholangiopancreatography (ERCP) and percutaneous transhepatic biliary drainage (PTBD), either alone or in combination, are acceptable for the preoperative management of hilar cholangiocarcinoma (HC) and can help optimize patients for curative HC resection, a recent study has found.
Treatment with the novel, selective peroxisome proliferator-activated receptor α modulator (SPPARMα) pemafibrate appears to produce a significant reduction in liver stiffness but not in liver fat content in patients with high-risk nonalcoholic fatty liver disease (NAFLD), according to the results of a phase II trial.
Hepatocellular carcinoma (HCC) in Singapore has changed markedly throughout the last decade, with patients being diagnosed at an increasingly older age and cryptogenic cirrhosis/nonalcoholic steatohepatitis (NASH) becoming a more important aetiology, according to a recent study.